In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotage AB

www.biotage.com

Latest From Biotage AB

Taking Stock Of Qiagen

Since its acquisition of Digene in 2007, Qiagen's business mix has shifted significantly towards molecular diagnostics even as the company remains true to its founding premise of making things simpler for customers. It has broadened its skill set in nucleic acid analysis with multiple acquired and licensed technologies for platform development while focusing on high volume tests in women's health and infectious diseases and new ties with pharma. Expect its acquisition pattern to continue.
Medical Device Business Strategies

With DxS, Qiagen Moves into Personalized Medicine

Qiagen has bought up DxS, a private UK-based provider of molecular tests including one for the mutant oncogene KRAS. Like the June 2009 deal by Labcorp. for Monogram Biosciences, it shows how IVD companies with very different business models are moving towards a common ground in personalized medicine and disease management.
Medical Device Platform Technologies

Australian Firm's Patents Snag Many Unwitting Infringers

A small Australian company called Genetic Technologies Corp. is shaking up just about everyone interested in genome scanning and genetic testing. Potentially, anyone who looks at genes in the context of their surrounding DNA in order to get more information about the gene infringes on GTG's patents. The company has begun successfully imposing licenses, sometimes via law suits.
BioPharmaceutical Medical Device

European Biotech M&A: Often Last Resort, but Welcome Nevertheless

Consolidation among Europe's biotech firms is picking up, but less for strategic reasons than simply to secure the cash to survive. Whatever the drivers, though, and however ruthless the concurrent cost- and program cutting, M&A should help create better adapted, bigger companies-something investors have long been calling for. Indeed for most merging companies, M&A is just the first step towards more strategic business-building moves in the near future.
BioPharmaceutical Europe
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register